MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.33
-0.68
-3.09%
Pre Market: 21.20 -0.13 -0.61% 08:00 03/04 EST
OPEN
22.10
PREV CLOSE
22.01
HIGH
22.14
LOW
21.31
VOLUME
257
TURNOVER
--
52 WEEK HIGH
27.80
52 WEEK LOW
13.67
MARKET CAP
6.65B
P/E (TTM)
61.10
1D
5D
1M
3M
1Y
5Y
8-K: EXELIXIS, INC.
(EDGAR Online via COMTEX) -- 2/25/20210000939767false12/3100009397672021-03-032021-03-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C....
Edgar Online - (EDK = 8-Ks/S1/S-4) · 14h ago
Insider Trends: Insider at Exelixis Converts Options in Mist of 90-Day Buying Trend
MT Newswires · 23h ago
Insider Trends: Exelixis Insider Sale Scaling Back 90-Day Buy Trend
MT Newswires · 23h ago
Wilms Tumor Market – Industry Analysis and Growth – Size, Share, Trends, Opportunities, Top Key Players Roche, Exelixis Inc, Agios Pharmaceutical, etc
Mar 02, 2021 (AB Digital via COMTEX) -- (Albany, US) DelveInsight has launched a new report on "Wilms Tumor Market Insights, Epidemiology, and Market...
ABNewswire · 1d ago
DJ Exelixis' CEO Mike Morrissey on Cowen 41st Annual Health Care Conference - Transcript >EXEL
Dow Jones · 2d ago
European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
Benzinga · 5d ago
Bristol Myers' opdivo + cabometyx wins positive opinion from EU in kidney cancer
The European Medicines Agency's advisory group CHMP has recommended approval of Bristol Myers Squibb's (BMY) Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for the first-line treatment of adults with advanced
Seekingalpha · 6d ago
DJ Bristol Myers: CHMP Backs Opdivo/Cabometyx in Advanced Renal Cell Carcinoma
Dow Jones · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXEL. Analyze the recent business situations of Exelixis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXEL stock price target is 31.17 with a high estimate of 37.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 582
Institutional Holdings: 279.05M
% Owned: 89.44%
Shares Outstanding: 311.99M
TypeInstitutionsShares
Increased
131
19.86M
New
97
1.05M
Decreased
111
13.50M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Co-Founder/Independent Director
Stelios Papadopoulos
Chief Executive Officer/President/Director
Michael Morrissey
Chief Financial Officer/Executive Vice President
Christopher Senner
Corporate Executive
Gisela Schwab
Executive Vice President/Chief Scientific Officer
Peter Lamb
Executive Vice President/General Counsel
Jeffrey Hessekiel
Executive Vice President
Patrick Haley
Independent Director
Charles Cohen
Independent Director
Carl Feldbaum
Independent Director
Maria Freire
Independent Director
Alan Garber
Independent Director
Vincent Marchesi
Independent Director
George Poste
Independent Director
Julie Smith
Independent Director
Lance Willsey
Independent Director
Jack Wyszomierski
No Data
About EXEL
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.